217 related articles for article (PubMed ID: 26996144)
21. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.
McEwan P; Bennett H; Ward T; Webster S; Gordon J; Kalsekar A; Yuan Y; Brenner M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):173-80. PubMed ID: 26545086
[TBL] [Abstract][Full Text] [Related]
22. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Deuffic-Burban S; Mathurin P; Pol S; Larsen C; Roudot-Thoraval F; Desenclos JC; Dhumeaux D; Yazdanpanah Y
Gut; 2012 Feb; 61(2):290-6. PubMed ID: 21930731
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
25. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
26. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
Stahmeyer JT; Rossol S; Bert F; Böker KH; Bruch HR; Eisenbach C; Link R; John C; Mauss S; Heyne R; Schott E; Pfeiffer-Vornkahl H; Hüppe D; Krauth C
PLoS One; 2016; 11(7):e0159976. PubMed ID: 27467772
[TBL] [Abstract][Full Text] [Related]
27. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population.
Mitra D; Davis KL; Beam C; Medjedovic J; Rustgi V
Value Health; 2010; 13(4):479-86. PubMed ID: 20102555
[TBL] [Abstract][Full Text] [Related]
28. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
[TBL] [Abstract][Full Text] [Related]
31. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.
Li X; Chan NS; Tam AW; Hung IFN; Chan EW
Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1801-1809. PubMed ID: 28516201
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
Cure S; Guerra I; Cammà C; Craxì A; Carosi G
J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
[TBL] [Abstract][Full Text] [Related]
33. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
34. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
[TBL] [Abstract][Full Text] [Related]
35. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
36. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
37. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
39. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]